-transparent.png){kind=logo}
Ten patients with AIDS and progressive cytomegalovirus disease were treated with ganciclovir and foscarnet concurrently. The patients had received ganciclovir and foscarnet monotherapy a median of 330 days before receiving combination therapy for a median of 80 days. Nine of the 10 patients responded to the combination. No electrolyte abnormalities were noted during combination therapy, but rates of neutropenia (relative rate, combination vs. ganciclovir, 1.99; P = .229) and thrombocytopenia (relative rate, combination vs. ganciclovir, 1.53; P = .616) were higher with combination therapy than with either drug alone. The relative rate of anemia was significantly increased with combination therapy compared with monotherapy (relative rate, combination vs. ganciclovir, 2.69; P = .025). These data suggest that combination ganciclovir and foscarnet therapy after failure of either alone appears to be as effective as standard therapy with single agents. The rate of anemia with combination therapy was significantly greater than either agent alone, but no significant difference was noted among the other parameters of toxicity studied.
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
August 1992,
Lancet (London, England),
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
February 1987,
The Journal of infectious diseases,
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
September 1994,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
June 1991,
The Journal of infectious diseases,
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
September 1995,
The Journal of infectious diseases,
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
August 1994,
The American journal of medicine,
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
November 1991,
American journal of hospital pharmacy,
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
August 1991,
AIDS (London, England),
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
November 1995,
Journal of medical virology,
D T Dieterich, and
M A Poles, and
E A Lew, and
P E Mendez, and
R Murphy, and
A Addessi, and
J T Holbrook, and
K Naughton, and
D N Friedberg
January 1995,
European journal of ophthalmology,
